Amgen Presents New Data From Phase 3 XGEVA ® (denosumab) Study In Multiple Myeloma Patients At The 16th International Myeloma Workshop

In this study, XGEVA® (denosumab) met the primary endpoint, demonstrating non-inferiority to zoledronic acid in delaying the time to first on-study skeletal-related event (SRE) in patients with multiple myeloma (HR=0.98, 95 percent CI: 0.85, 1....
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news